nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—kidney cancer—pancreatic cancer	0.35	1	CtDrD
Erlotinib—EGFR—pancreatic cancer	0.151	1	CbGaD
Erlotinib—ULK3—Sunitinib—pancreatic cancer	0.0393	0.108	CbGbCtD
Erlotinib—TNK1—Sunitinib—pancreatic cancer	0.0393	0.108	CbGbCtD
Erlotinib—AURKC—Sunitinib—pancreatic cancer	0.0312	0.0859	CbGbCtD
Erlotinib—SLK—Sunitinib—pancreatic cancer	0.0261	0.0718	CbGbCtD
Erlotinib—FLT3—Sunitinib—pancreatic cancer	0.0226	0.0621	CbGbCtD
Erlotinib—HIPK4—Sunitinib—pancreatic cancer	0.02	0.0549	CbGbCtD
Erlotinib—EGFR—Docetaxel—pancreatic cancer	0.018	0.0495	CbGbCtD
Erlotinib—STK10—Sunitinib—pancreatic cancer	0.0179	0.0493	CbGbCtD
Erlotinib—NR1I2—Docetaxel—pancreatic cancer	0.0164	0.0451	CbGbCtD
Erlotinib—MAP2K5—Sunitinib—pancreatic cancer	0.0163	0.0449	CbGbCtD
Erlotinib—MAP3K19—Sunitinib—pancreatic cancer	0.015	0.0413	CbGbCtD
Erlotinib—CYP1B1—Tamoxifen—pancreatic cancer	0.0111	0.0306	CbGbCtD
Erlotinib—UGT1A1—Irinotecan—pancreatic cancer	0.00738	0.0203	CbGbCtD
Erlotinib—CYP1B1—Docetaxel—pancreatic cancer	0.00626	0.0172	CbGbCtD
Erlotinib—CYP1A1—Dacarbazine—pancreatic cancer	0.00613	0.0169	CbGbCtD
Erlotinib—ABCG2—Tamoxifen—pancreatic cancer	0.00529	0.0145	CbGbCtD
Erlotinib—CYP1A1—Tamoxifen—pancreatic cancer	0.00488	0.0134	CbGbCtD
Erlotinib—CYP1B1—Doxorubicin—pancreatic cancer	0.00467	0.0128	CbGbCtD
Erlotinib—ABCG2—Irinotecan—pancreatic cancer	0.00406	0.0112	CbGbCtD
Erlotinib—ABCG2—Fluorouracil—pancreatic cancer	0.0039	0.0107	CbGbCtD
Erlotinib—ABCG2—Docetaxel—pancreatic cancer	0.00298	0.00818	CbGbCtD
Erlotinib—ABCG2—Sunitinib—pancreatic cancer	0.00296	0.00814	CbGbCtD
Erlotinib—CYP3A5—Tamoxifen—pancreatic cancer	0.00293	0.00806	CbGbCtD
Erlotinib—CYP2C8—Tamoxifen—pancreatic cancer	0.00282	0.00775	CbGbCtD
Erlotinib—ALB—Irinotecan—pancreatic cancer	0.0028	0.0077	CbGbCtD
Erlotinib—CYP1A2—Dacarbazine—pancreatic cancer	0.00274	0.00754	CbGbCtD
Erlotinib—ALB—Fluorouracil—pancreatic cancer	0.00269	0.00739	CbGbCtD
Erlotinib—CYP3A5—Irinotecan—pancreatic cancer	0.00225	0.00619	CbGbCtD
Erlotinib—ABCG2—Doxorubicin—pancreatic cancer	0.00222	0.0061	CbGbCtD
Erlotinib—CYP1A2—Tamoxifen—pancreatic cancer	0.00218	0.006	CbGbCtD
Erlotinib—CYP2C8—Fluorouracil—pancreatic cancer	0.00208	0.00571	CbGbCtD
Erlotinib—ABCB1—Tamoxifen—pancreatic cancer	0.00191	0.00524	CbGbCtD
Erlotinib—CYP2D6—Tamoxifen—pancreatic cancer	0.0018	0.00494	CbGbCtD
Erlotinib—CYP3A5—Docetaxel—pancreatic cancer	0.00165	0.00453	CbGbCtD
Erlotinib—ABCB1—Gemcitabine—pancreatic cancer	0.00164	0.00452	CbGbCtD
Erlotinib—CYP3A5—Sunitinib—pancreatic cancer	0.00164	0.00451	CbGbCtD
Erlotinib—CYP1A2—Fluorouracil—pancreatic cancer	0.00161	0.00442	CbGbCtD
Erlotinib—ORM1—bile—pancreatic cancer	0.00151	0.197	CbGeAlD
Erlotinib—ABCB1—Irinotecan—pancreatic cancer	0.00146	0.00403	CbGbCtD
Erlotinib—CYP3A4—Tamoxifen—pancreatic cancer	0.00114	0.00314	CbGbCtD
Erlotinib—ABCB1—Docetaxel—pancreatic cancer	0.00107	0.00295	CbGbCtD
Erlotinib—ABCB1—Sunitinib—pancreatic cancer	0.00107	0.00294	CbGbCtD
Erlotinib—CYP3A4—Irinotecan—pancreatic cancer	0.000877	0.00241	CbGbCtD
Erlotinib—ABCB1—Doxorubicin—pancreatic cancer	0.0008	0.0022	CbGbCtD
Erlotinib—CYP2D6—Doxorubicin—pancreatic cancer	0.000754	0.00207	CbGbCtD
Erlotinib—CYP3A4—Docetaxel—pancreatic cancer	0.000643	0.00177	CbGbCtD
Erlotinib—CYP3A4—Sunitinib—pancreatic cancer	0.00064	0.00176	CbGbCtD
Erlotinib—ABL1—Topotecan—Irinotecan—pancreatic cancer	0.000624	0.424	CbGdCrCtD
Erlotinib—NR1I2—digestive system—pancreatic cancer	0.000539	0.0705	CbGeAlD
Erlotinib—Vandetanib—SRC—pancreatic cancer	0.000517	0.247	CrCbGaD
Erlotinib—PIP4K2C—islet of Langerhans—pancreatic cancer	0.000512	0.0669	CbGeAlD
Erlotinib—Vandetanib—KDR—pancreatic cancer	0.000485	0.232	CrCbGaD
Erlotinib—CYP3A4—Doxorubicin—pancreatic cancer	0.000479	0.00132	CbGbCtD
Erlotinib—SLK—islet of Langerhans—pancreatic cancer	0.000435	0.057	CbGeAlD
Erlotinib—JAK3—digestive system—pancreatic cancer	0.000431	0.0564	CbGeAlD
Erlotinib—ORM1—gall bladder—pancreatic cancer	0.000419	0.0548	CbGeAlD
Erlotinib—Vandetanib—VEGFA—pancreatic cancer	0.000412	0.197	CrCbGaD
Erlotinib—ALB—gall bladder—pancreatic cancer	0.000367	0.048	CbGeAlD
Erlotinib—PIP4K2C—pancreas—pancreatic cancer	0.00036	0.047	CbGeAlD
Erlotinib—Vandetanib—EGFR—pancreatic cancer	0.000347	0.166	CrCbGaD
Erlotinib—Gefitinib—EGFR—pancreatic cancer	0.00033	0.158	CrCbGaD
Erlotinib—SLK—pancreas—pancreatic cancer	0.000306	0.04	CbGeAlD
Erlotinib—ULK3—digestive system—pancreatic cancer	0.000293	0.0384	CbGeAlD
Erlotinib—MKNK1—digestive system—pancreatic cancer	0.000276	0.0361	CbGeAlD
Erlotinib—ABL1—islet of Langerhans—pancreatic cancer	0.000261	0.0341	CbGeAlD
Erlotinib—STK10—digestive system—pancreatic cancer	0.000227	0.0297	CbGeAlD
Erlotinib—UGT1A1—digestive system—pancreatic cancer	0.000215	0.0281	CbGeAlD
Erlotinib—ABL1—pancreas—pancreatic cancer	0.000183	0.024	CbGeAlD
Erlotinib—SLCO2B1—digestive system—pancreatic cancer	0.000158	0.0207	CbGeAlD
Erlotinib—ABL1—digestive system—pancreatic cancer	0.000157	0.0205	CbGeAlD
Erlotinib—CYP3A5—islet of Langerhans—pancreatic cancer	0.000153	0.02	CbGeAlD
Erlotinib—ABL1—Doxorubicin—Epirubicin—pancreatic cancer	0.000147	0.0997	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Epirubicin—pancreatic cancer	0.000147	0.0997	CbGdCrCtD
Erlotinib—ABL1—Idarubicin—Epirubicin—pancreatic cancer	0.000147	0.0997	CbGdCrCtD
Erlotinib—ABL1—Idarubicin—Doxorubicin—pancreatic cancer	0.000136	0.0923	CbGdCrCtD
Erlotinib—ABL1—Epirubicin—Doxorubicin—pancreatic cancer	0.000136	0.0923	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Doxorubicin—pancreatic cancer	0.000136	0.0923	CbGdCrCtD
Erlotinib—CYP1B1—digestive system—pancreatic cancer	0.000133	0.0173	CbGeAlD
Erlotinib—CYP3A5—pancreas—pancreatic cancer	0.000107	0.014	CbGeAlD
Erlotinib—CYP1A2—digestive system—pancreatic cancer	9.5e-05	0.0124	CbGeAlD
Erlotinib—CYP1A1—digestive system—pancreatic cancer	9.38e-05	0.0123	CbGeAlD
Erlotinib—CYP3A5—digestive system—pancreatic cancer	9.17e-05	0.012	CbGeAlD
Erlotinib—ABCB1—islet of Langerhans—pancreatic cancer	8.11e-05	0.0106	CbGeAlD
Erlotinib—CYP3A4—digestive system—pancreatic cancer	6.88e-05	0.009	CbGeAlD
Erlotinib—CYP2D6—digestive system—pancreatic cancer	6.77e-05	0.00886	CbGeAlD
Erlotinib—ABCB1—pancreas—pancreatic cancer	5.7e-05	0.00746	CbGeAlD
Erlotinib—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	5.5e-05	0.000755	CcSEcCtD
Erlotinib—Dehydration—Epirubicin—pancreatic cancer	5.46e-05	0.000751	CcSEcCtD
Erlotinib—Insomnia—Gemcitabine—pancreatic cancer	5.46e-05	0.00075	CcSEcCtD
Erlotinib—Dyspepsia—Irinotecan—pancreatic cancer	5.45e-05	0.000749	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Doxorubicin—pancreatic cancer	5.44e-05	0.000747	CcSEcCtD
Erlotinib—Mediastinal disorder—Docetaxel—pancreatic cancer	5.43e-05	0.000746	CcSEcCtD
Erlotinib—Chills—Docetaxel—pancreatic cancer	5.41e-05	0.000743	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	5.41e-05	0.000743	CcSEcCtD
Erlotinib—Asthenia—Sunitinib—pancreatic cancer	5.4e-05	0.000741	CcSEcCtD
Erlotinib—Dry skin—Epirubicin—pancreatic cancer	5.39e-05	0.00074	CcSEcCtD
Erlotinib—Decreased appetite—Irinotecan—pancreatic cancer	5.38e-05	0.00074	CcSEcCtD
Erlotinib—Arrhythmia—Docetaxel—pancreatic cancer	5.38e-05	0.00074	CcSEcCtD
Erlotinib—Dyspnoea—Gemcitabine—pancreatic cancer	5.38e-05	0.000739	CcSEcCtD
Erlotinib—Insomnia—Fluorouracil—pancreatic cancer	5.37e-05	0.000737	CcSEcCtD
Erlotinib—Hypokalaemia—Epirubicin—pancreatic cancer	5.35e-05	0.000735	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Irinotecan—pancreatic cancer	5.35e-05	0.000735	CcSEcCtD
Erlotinib—Fatigue—Irinotecan—pancreatic cancer	5.34e-05	0.000734	CcSEcCtD
Erlotinib—Alopecia—Docetaxel—pancreatic cancer	5.33e-05	0.000732	CcSEcCtD
Erlotinib—Pruritus—Sunitinib—pancreatic cancer	5.32e-05	0.000731	CcSEcCtD
Erlotinib—Pain—Irinotecan—pancreatic cancer	5.3e-05	0.000728	CcSEcCtD
Erlotinib—Constipation—Irinotecan—pancreatic cancer	5.3e-05	0.000728	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Epirubicin—pancreatic cancer	5.29e-05	0.000727	CcSEcCtD
Erlotinib—Dyspnoea—Fluorouracil—pancreatic cancer	5.29e-05	0.000727	CcSEcCtD
Erlotinib—Mental disorder—Docetaxel—pancreatic cancer	5.28e-05	0.000726	CcSEcCtD
Erlotinib—Erythema—Docetaxel—pancreatic cancer	5.25e-05	0.000721	CcSEcCtD
Erlotinib—Malnutrition—Docetaxel—pancreatic cancer	5.25e-05	0.000721	CcSEcCtD
Erlotinib—Decreased appetite—Gemcitabine—pancreatic cancer	5.25e-05	0.000721	CcSEcCtD
Erlotinib—Dyspepsia—Fluorouracil—pancreatic cancer	5.22e-05	0.000718	CcSEcCtD
Erlotinib—Nausea—Tamoxifen—pancreatic cancer	5.22e-05	0.000717	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	5.21e-05	0.000716	CcSEcCtD
Erlotinib—Fatigue—Gemcitabine—pancreatic cancer	5.2e-05	0.000715	CcSEcCtD
Erlotinib—Gastritis—Epirubicin—pancreatic cancer	5.2e-05	0.000715	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	5.18e-05	0.000712	CcSEcCtD
Erlotinib—Constipation—Gemcitabine—pancreatic cancer	5.16e-05	0.000709	CcSEcCtD
Erlotinib—Pain—Gemcitabine—pancreatic cancer	5.16e-05	0.000709	CcSEcCtD
Erlotinib—Decreased appetite—Fluorouracil—pancreatic cancer	5.16e-05	0.000709	CcSEcCtD
Erlotinib—Diarrhoea—Sunitinib—pancreatic cancer	5.15e-05	0.000707	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	5.12e-05	0.000704	CcSEcCtD
Erlotinib—Dysphagia—Epirubicin—pancreatic cancer	5.08e-05	0.000698	CcSEcCtD
Erlotinib—Back pain—Docetaxel—pancreatic cancer	5.07e-05	0.000697	CcSEcCtD
Erlotinib—Pain—Fluorouracil—pancreatic cancer	5.07e-05	0.000697	CcSEcCtD
Erlotinib—Gastrointestinal pain—Irinotecan—pancreatic cancer	5.07e-05	0.000696	CcSEcCtD
Erlotinib—Dehydration—Doxorubicin—pancreatic cancer	5.06e-05	0.000695	CcSEcCtD
Erlotinib—Dry skin—Doxorubicin—pancreatic cancer	4.98e-05	0.000685	CcSEcCtD
Erlotinib—Pancreatitis—Epirubicin—pancreatic cancer	4.98e-05	0.000684	CcSEcCtD
Erlotinib—Dizziness—Sunitinib—pancreatic cancer	4.97e-05	0.000683	CcSEcCtD
Erlotinib—Hypokalaemia—Doxorubicin—pancreatic cancer	4.95e-05	0.00068	CcSEcCtD
Erlotinib—Abdominal pain—Irinotecan—pancreatic cancer	4.9e-05	0.000673	CcSEcCtD
Erlotinib—Body temperature increased—Irinotecan—pancreatic cancer	4.9e-05	0.000673	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	4.9e-05	0.000673	CcSEcCtD
Erlotinib—ABCB1—digestive system—pancreatic cancer	4.87e-05	0.00637	CbGeAlD
Erlotinib—Gastritis—Doxorubicin—pancreatic cancer	4.81e-05	0.000661	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	4.8e-05	0.000659	CcSEcCtD
Erlotinib—Vomiting—Sunitinib—pancreatic cancer	4.78e-05	0.000657	CcSEcCtD
Erlotinib—Body temperature increased—Gemcitabine—pancreatic cancer	4.77e-05	0.000656	CcSEcCtD
Erlotinib—Neutropenia—Epirubicin—pancreatic cancer	4.75e-05	0.000653	CcSEcCtD
Erlotinib—Rash—Sunitinib—pancreatic cancer	4.74e-05	0.000652	CcSEcCtD
Erlotinib—Dermatitis—Sunitinib—pancreatic cancer	4.74e-05	0.000651	CcSEcCtD
Erlotinib—Headache—Sunitinib—pancreatic cancer	4.71e-05	0.000647	CcSEcCtD
Erlotinib—Syncope—Docetaxel—pancreatic cancer	4.71e-05	0.000647	CcSEcCtD
Erlotinib—Dysphagia—Doxorubicin—pancreatic cancer	4.7e-05	0.000646	CcSEcCtD
Erlotinib—Body temperature increased—Fluorouracil—pancreatic cancer	4.69e-05	0.000645	CcSEcCtD
Erlotinib—Loss of consciousness—Docetaxel—pancreatic cancer	4.61e-05	0.000634	CcSEcCtD
Erlotinib—Pancreatitis—Doxorubicin—pancreatic cancer	4.61e-05	0.000633	CcSEcCtD
Erlotinib—Weight decreased—Epirubicin—pancreatic cancer	4.59e-05	0.000631	CcSEcCtD
Erlotinib—Cough—Docetaxel—pancreatic cancer	4.58e-05	0.000629	CcSEcCtD
Erlotinib—Pneumonia—Epirubicin—pancreatic cancer	4.55e-05	0.000626	CcSEcCtD
Erlotinib—Infestation NOS—Epirubicin—pancreatic cancer	4.53e-05	0.000622	CcSEcCtD
Erlotinib—Infestation—Epirubicin—pancreatic cancer	4.53e-05	0.000622	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	4.49e-05	0.000617	CcSEcCtD
Erlotinib—Myalgia—Docetaxel—pancreatic cancer	4.47e-05	0.000614	CcSEcCtD
Erlotinib—Arthralgia—Docetaxel—pancreatic cancer	4.47e-05	0.000614	CcSEcCtD
Erlotinib—Chest pain—Docetaxel—pancreatic cancer	4.47e-05	0.000614	CcSEcCtD
Erlotinib—Nausea—Sunitinib—pancreatic cancer	4.47e-05	0.000614	CcSEcCtD
Erlotinib—Renal failure—Epirubicin—pancreatic cancer	4.45e-05	0.000612	CcSEcCtD
Erlotinib—Asthenia—Irinotecan—pancreatic cancer	4.44e-05	0.000611	CcSEcCtD
Erlotinib—Neuropathy peripheral—Epirubicin—pancreatic cancer	4.44e-05	0.00061	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	4.44e-05	0.00061	CcSEcCtD
Erlotinib—Stomatitis—Epirubicin—pancreatic cancer	4.41e-05	0.000607	CcSEcCtD
Erlotinib—Conjunctivitis—Epirubicin—pancreatic cancer	4.4e-05	0.000605	CcSEcCtD
Erlotinib—Neutropenia—Doxorubicin—pancreatic cancer	4.39e-05	0.000604	CcSEcCtD
Erlotinib—Asthenia—Gemcitabine—pancreatic cancer	4.33e-05	0.000595	CcSEcCtD
Erlotinib—Hepatobiliary disease—Epirubicin—pancreatic cancer	4.28e-05	0.000589	CcSEcCtD
Erlotinib—Oedema—Docetaxel—pancreatic cancer	4.28e-05	0.000588	CcSEcCtD
Erlotinib—Epistaxis—Epirubicin—pancreatic cancer	4.27e-05	0.000587	CcSEcCtD
Erlotinib—Pruritus—Gemcitabine—pancreatic cancer	4.27e-05	0.000587	CcSEcCtD
Erlotinib—Infection—Docetaxel—pancreatic cancer	4.25e-05	0.000585	CcSEcCtD
Erlotinib—Weight decreased—Doxorubicin—pancreatic cancer	4.25e-05	0.000584	CcSEcCtD
Erlotinib—Diarrhoea—Irinotecan—pancreatic cancer	4.24e-05	0.000582	CcSEcCtD
Erlotinib—Pneumonia—Doxorubicin—pancreatic cancer	4.21e-05	0.000579	CcSEcCtD
Erlotinib—Shock—Docetaxel—pancreatic cancer	4.21e-05	0.000579	CcSEcCtD
Erlotinib—Nervous system disorder—Docetaxel—pancreatic cancer	4.2e-05	0.000577	CcSEcCtD
Erlotinib—Pruritus—Fluorouracil—pancreatic cancer	4.2e-05	0.000577	CcSEcCtD
Erlotinib—Thrombocytopenia—Docetaxel—pancreatic cancer	4.19e-05	0.000576	CcSEcCtD
Erlotinib—Infestation NOS—Doxorubicin—pancreatic cancer	4.19e-05	0.000576	CcSEcCtD
Erlotinib—Infestation—Doxorubicin—pancreatic cancer	4.19e-05	0.000576	CcSEcCtD
Erlotinib—Skin disorder—Docetaxel—pancreatic cancer	4.16e-05	0.000572	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	4.15e-05	0.000571	CcSEcCtD
Erlotinib—Diarrhoea—Gemcitabine—pancreatic cancer	4.13e-05	0.000567	CcSEcCtD
Erlotinib—Renal failure—Doxorubicin—pancreatic cancer	4.12e-05	0.000566	CcSEcCtD
Erlotinib—Neuropathy peripheral—Doxorubicin—pancreatic cancer	4.11e-05	0.000564	CcSEcCtD
Erlotinib—Dizziness—Irinotecan—pancreatic cancer	4.1e-05	0.000563	CcSEcCtD
Erlotinib—Haemoglobin—Epirubicin—pancreatic cancer	4.09e-05	0.000562	CcSEcCtD
Erlotinib—Stomatitis—Doxorubicin—pancreatic cancer	4.08e-05	0.000561	CcSEcCtD
Erlotinib—Anorexia—Docetaxel—pancreatic cancer	4.08e-05	0.000561	CcSEcCtD
Erlotinib—Conjunctivitis—Doxorubicin—pancreatic cancer	4.07e-05	0.00056	CcSEcCtD
Erlotinib—Haemorrhage—Epirubicin—pancreatic cancer	4.07e-05	0.000559	CcSEcCtD
Erlotinib—Hepatitis—Epirubicin—pancreatic cancer	4.07e-05	0.000559	CcSEcCtD
Erlotinib—Diarrhoea—Fluorouracil—pancreatic cancer	4.06e-05	0.000558	CcSEcCtD
Erlotinib—Urinary tract disorder—Epirubicin—pancreatic cancer	4.01e-05	0.000552	CcSEcCtD
Erlotinib—Connective tissue disorder—Epirubicin—pancreatic cancer	3.99e-05	0.000549	CcSEcCtD
Erlotinib—Urethral disorder—Epirubicin—pancreatic cancer	3.98e-05	0.000548	CcSEcCtD
Erlotinib—Hepatobiliary disease—Doxorubicin—pancreatic cancer	3.96e-05	0.000545	CcSEcCtD
Erlotinib—Epistaxis—Doxorubicin—pancreatic cancer	3.95e-05	0.000543	CcSEcCtD
Erlotinib—Vomiting—Irinotecan—pancreatic cancer	3.94e-05	0.000541	CcSEcCtD
Erlotinib—Dizziness—Fluorouracil—pancreatic cancer	3.92e-05	0.000539	CcSEcCtD
Erlotinib—Rash—Irinotecan—pancreatic cancer	3.91e-05	0.000537	CcSEcCtD
Erlotinib—Dermatitis—Irinotecan—pancreatic cancer	3.9e-05	0.000536	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	3.9e-05	0.000536	CcSEcCtD
Erlotinib—Headache—Irinotecan—pancreatic cancer	3.88e-05	0.000533	CcSEcCtD
Erlotinib—Insomnia—Docetaxel—pancreatic cancer	3.87e-05	0.000532	CcSEcCtD
Erlotinib—Erythema multiforme—Epirubicin—pancreatic cancer	3.84e-05	0.000528	CcSEcCtD
Erlotinib—Vomiting—Gemcitabine—pancreatic cancer	3.84e-05	0.000527	CcSEcCtD
Erlotinib—Dyspnoea—Docetaxel—pancreatic cancer	3.82e-05	0.000525	CcSEcCtD
Erlotinib—Rash—Gemcitabine—pancreatic cancer	3.8e-05	0.000523	CcSEcCtD
Erlotinib—Dermatitis—Gemcitabine—pancreatic cancer	3.8e-05	0.000522	CcSEcCtD
Erlotinib—Eye disorder—Epirubicin—pancreatic cancer	3.8e-05	0.000522	CcSEcCtD
Erlotinib—Haemoglobin—Doxorubicin—pancreatic cancer	3.78e-05	0.00052	CcSEcCtD
Erlotinib—Headache—Gemcitabine—pancreatic cancer	3.78e-05	0.000519	CcSEcCtD
Erlotinib—Vomiting—Fluorouracil—pancreatic cancer	3.77e-05	0.000518	CcSEcCtD
Erlotinib—Dyspepsia—Docetaxel—pancreatic cancer	3.77e-05	0.000518	CcSEcCtD
Erlotinib—Haemorrhage—Doxorubicin—pancreatic cancer	3.76e-05	0.000517	CcSEcCtD
Erlotinib—Hepatitis—Doxorubicin—pancreatic cancer	3.76e-05	0.000517	CcSEcCtD
Erlotinib—Rash—Fluorouracil—pancreatic cancer	3.74e-05	0.000514	CcSEcCtD
Erlotinib—Dermatitis—Fluorouracil—pancreatic cancer	3.74e-05	0.000514	CcSEcCtD
Erlotinib—Decreased appetite—Docetaxel—pancreatic cancer	3.72e-05	0.000512	CcSEcCtD
Erlotinib—Headache—Fluorouracil—pancreatic cancer	3.72e-05	0.000511	CcSEcCtD
Erlotinib—Urinary tract disorder—Doxorubicin—pancreatic cancer	3.71e-05	0.000511	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Docetaxel—pancreatic cancer	3.7e-05	0.000508	CcSEcCtD
Erlotinib—Connective tissue disorder—Doxorubicin—pancreatic cancer	3.7e-05	0.000508	CcSEcCtD
Erlotinib—Fatigue—Docetaxel—pancreatic cancer	3.69e-05	0.000507	CcSEcCtD
Erlotinib—Urethral disorder—Doxorubicin—pancreatic cancer	3.69e-05	0.000507	CcSEcCtD
Erlotinib—Nausea—Irinotecan—pancreatic cancer	3.68e-05	0.000506	CcSEcCtD
Erlotinib—Mediastinal disorder—Epirubicin—pancreatic cancer	3.66e-05	0.000504	CcSEcCtD
Erlotinib—Constipation—Docetaxel—pancreatic cancer	3.66e-05	0.000503	CcSEcCtD
Erlotinib—Pain—Docetaxel—pancreatic cancer	3.66e-05	0.000503	CcSEcCtD
Erlotinib—Chills—Epirubicin—pancreatic cancer	3.65e-05	0.000501	CcSEcCtD
Erlotinib—Arrhythmia—Epirubicin—pancreatic cancer	3.63e-05	0.000499	CcSEcCtD
Erlotinib—Alopecia—Epirubicin—pancreatic cancer	3.59e-05	0.000494	CcSEcCtD
Erlotinib—Nausea—Gemcitabine—pancreatic cancer	3.58e-05	0.000493	CcSEcCtD
Erlotinib—Mental disorder—Epirubicin—pancreatic cancer	3.56e-05	0.000489	CcSEcCtD
Erlotinib—Erythema multiforme—Doxorubicin—pancreatic cancer	3.56e-05	0.000489	CcSEcCtD
Erlotinib—Erythema—Epirubicin—pancreatic cancer	3.54e-05	0.000486	CcSEcCtD
Erlotinib—Malnutrition—Epirubicin—pancreatic cancer	3.54e-05	0.000486	CcSEcCtD
Erlotinib—Nausea—Fluorouracil—pancreatic cancer	3.52e-05	0.000484	CcSEcCtD
Erlotinib—Eye disorder—Doxorubicin—pancreatic cancer	3.52e-05	0.000483	CcSEcCtD
Erlotinib—Gastrointestinal pain—Docetaxel—pancreatic cancer	3.5e-05	0.000481	CcSEcCtD
Erlotinib—Flatulence—Epirubicin—pancreatic cancer	3.49e-05	0.000479	CcSEcCtD
Erlotinib—Back pain—Epirubicin—pancreatic cancer	3.42e-05	0.00047	CcSEcCtD
Erlotinib—Mediastinal disorder—Doxorubicin—pancreatic cancer	3.39e-05	0.000466	CcSEcCtD
Erlotinib—Abdominal pain—Docetaxel—pancreatic cancer	3.38e-05	0.000465	CcSEcCtD
Erlotinib—Body temperature increased—Docetaxel—pancreatic cancer	3.38e-05	0.000465	CcSEcCtD
Erlotinib—Chills—Doxorubicin—pancreatic cancer	3.37e-05	0.000464	CcSEcCtD
Erlotinib—Arrhythmia—Doxorubicin—pancreatic cancer	3.36e-05	0.000462	CcSEcCtD
Erlotinib—Alopecia—Doxorubicin—pancreatic cancer	3.32e-05	0.000457	CcSEcCtD
Erlotinib—Mental disorder—Doxorubicin—pancreatic cancer	3.3e-05	0.000453	CcSEcCtD
Erlotinib—Malnutrition—Doxorubicin—pancreatic cancer	3.27e-05	0.00045	CcSEcCtD
Erlotinib—Erythema—Doxorubicin—pancreatic cancer	3.27e-05	0.00045	CcSEcCtD
Erlotinib—Flatulence—Doxorubicin—pancreatic cancer	3.23e-05	0.000443	CcSEcCtD
Erlotinib—Syncope—Epirubicin—pancreatic cancer	3.17e-05	0.000436	CcSEcCtD
Erlotinib—Back pain—Doxorubicin—pancreatic cancer	3.17e-05	0.000435	CcSEcCtD
Erlotinib—Loss of consciousness—Epirubicin—pancreatic cancer	3.11e-05	0.000427	CcSEcCtD
Erlotinib—Cough—Epirubicin—pancreatic cancer	3.09e-05	0.000424	CcSEcCtD
Erlotinib—Asthenia—Docetaxel—pancreatic cancer	3.07e-05	0.000422	CcSEcCtD
Erlotinib—Pruritus—Docetaxel—pancreatic cancer	3.03e-05	0.000416	CcSEcCtD
Erlotinib—Myalgia—Epirubicin—pancreatic cancer	3.01e-05	0.000414	CcSEcCtD
Erlotinib—Arthralgia—Epirubicin—pancreatic cancer	3.01e-05	0.000414	CcSEcCtD
Erlotinib—Chest pain—Epirubicin—pancreatic cancer	3.01e-05	0.000414	CcSEcCtD
Erlotinib—Anxiety—Epirubicin—pancreatic cancer	3e-05	0.000413	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	2.99e-05	0.000411	CcSEcCtD
Erlotinib—Syncope—Doxorubicin—pancreatic cancer	2.94e-05	0.000404	CcSEcCtD
Erlotinib—Diarrhoea—Docetaxel—pancreatic cancer	2.93e-05	0.000403	CcSEcCtD
Erlotinib—Oedema—Epirubicin—pancreatic cancer	2.89e-05	0.000397	CcSEcCtD
Erlotinib—Loss of consciousness—Doxorubicin—pancreatic cancer	2.88e-05	0.000396	CcSEcCtD
Erlotinib—Infection—Epirubicin—pancreatic cancer	2.87e-05	0.000394	CcSEcCtD
Erlotinib—Cough—Doxorubicin—pancreatic cancer	2.86e-05	0.000393	CcSEcCtD
Erlotinib—Shock—Epirubicin—pancreatic cancer	2.84e-05	0.000391	CcSEcCtD
Erlotinib—Nervous system disorder—Epirubicin—pancreatic cancer	2.83e-05	0.000389	CcSEcCtD
Erlotinib—Dizziness—Docetaxel—pancreatic cancer	2.83e-05	0.000389	CcSEcCtD
Erlotinib—Thrombocytopenia—Epirubicin—pancreatic cancer	2.83e-05	0.000389	CcSEcCtD
Erlotinib—Skin disorder—Epirubicin—pancreatic cancer	2.81e-05	0.000386	CcSEcCtD
Erlotinib—Chest pain—Doxorubicin—pancreatic cancer	2.79e-05	0.000383	CcSEcCtD
Erlotinib—Myalgia—Doxorubicin—pancreatic cancer	2.79e-05	0.000383	CcSEcCtD
Erlotinib—Arthralgia—Doxorubicin—pancreatic cancer	2.79e-05	0.000383	CcSEcCtD
Erlotinib—Anxiety—Doxorubicin—pancreatic cancer	2.78e-05	0.000382	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	2.77e-05	0.00038	CcSEcCtD
Erlotinib—Anorexia—Epirubicin—pancreatic cancer	2.75e-05	0.000378	CcSEcCtD
Erlotinib—Vomiting—Docetaxel—pancreatic cancer	2.72e-05	0.000374	CcSEcCtD
Erlotinib—Rash—Docetaxel—pancreatic cancer	2.7e-05	0.000371	CcSEcCtD
Erlotinib—Dermatitis—Docetaxel—pancreatic cancer	2.7e-05	0.000371	CcSEcCtD
Erlotinib—Headache—Docetaxel—pancreatic cancer	2.68e-05	0.000369	CcSEcCtD
Erlotinib—Oedema—Doxorubicin—pancreatic cancer	2.67e-05	0.000367	CcSEcCtD
Erlotinib—Infection—Doxorubicin—pancreatic cancer	2.65e-05	0.000365	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	2.63e-05	0.000362	CcSEcCtD
Erlotinib—Shock—Doxorubicin—pancreatic cancer	2.63e-05	0.000361	CcSEcCtD
Erlotinib—Nervous system disorder—Doxorubicin—pancreatic cancer	2.62e-05	0.00036	CcSEcCtD
Erlotinib—Thrombocytopenia—Doxorubicin—pancreatic cancer	2.62e-05	0.00036	CcSEcCtD
Erlotinib—Insomnia—Epirubicin—pancreatic cancer	2.61e-05	0.000359	CcSEcCtD
Erlotinib—Skin disorder—Doxorubicin—pancreatic cancer	2.6e-05	0.000357	CcSEcCtD
Erlotinib—Dyspnoea—Epirubicin—pancreatic cancer	2.57e-05	0.000354	CcSEcCtD
Erlotinib—Anorexia—Doxorubicin—pancreatic cancer	2.55e-05	0.00035	CcSEcCtD
Erlotinib—Nausea—Docetaxel—pancreatic cancer	2.54e-05	0.00035	CcSEcCtD
Erlotinib—Dyspepsia—Epirubicin—pancreatic cancer	2.54e-05	0.000349	CcSEcCtD
Erlotinib—Decreased appetite—Epirubicin—pancreatic cancer	2.51e-05	0.000345	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Epirubicin—pancreatic cancer	2.49e-05	0.000343	CcSEcCtD
Erlotinib—Fatigue—Epirubicin—pancreatic cancer	2.49e-05	0.000342	CcSEcCtD
Erlotinib—Constipation—Epirubicin—pancreatic cancer	2.47e-05	0.000339	CcSEcCtD
Erlotinib—Pain—Epirubicin—pancreatic cancer	2.47e-05	0.000339	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	2.43e-05	0.000335	CcSEcCtD
Erlotinib—Insomnia—Doxorubicin—pancreatic cancer	2.42e-05	0.000332	CcSEcCtD
Erlotinib—Dyspnoea—Doxorubicin—pancreatic cancer	2.38e-05	0.000327	CcSEcCtD
Erlotinib—Gastrointestinal pain—Epirubicin—pancreatic cancer	2.36e-05	0.000325	CcSEcCtD
Erlotinib—Dyspepsia—Doxorubicin—pancreatic cancer	2.35e-05	0.000323	CcSEcCtD
Erlotinib—Decreased appetite—Doxorubicin—pancreatic cancer	2.32e-05	0.000319	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	2.31e-05	0.000317	CcSEcCtD
Erlotinib—Fatigue—Doxorubicin—pancreatic cancer	2.3e-05	0.000317	CcSEcCtD
Erlotinib—Constipation—Doxorubicin—pancreatic cancer	2.29e-05	0.000314	CcSEcCtD
Erlotinib—Pain—Doxorubicin—pancreatic cancer	2.29e-05	0.000314	CcSEcCtD
Erlotinib—Abdominal pain—Epirubicin—pancreatic cancer	2.28e-05	0.000314	CcSEcCtD
Erlotinib—Body temperature increased—Epirubicin—pancreatic cancer	2.28e-05	0.000314	CcSEcCtD
Erlotinib—Gastrointestinal pain—Doxorubicin—pancreatic cancer	2.19e-05	0.0003	CcSEcCtD
Erlotinib—Abdominal pain—Doxorubicin—pancreatic cancer	2.11e-05	0.00029	CcSEcCtD
Erlotinib—Body temperature increased—Doxorubicin—pancreatic cancer	2.11e-05	0.00029	CcSEcCtD
Erlotinib—Asthenia—Epirubicin—pancreatic cancer	2.07e-05	0.000285	CcSEcCtD
Erlotinib—Pruritus—Epirubicin—pancreatic cancer	2.04e-05	0.000281	CcSEcCtD
Erlotinib—Diarrhoea—Epirubicin—pancreatic cancer	1.98e-05	0.000272	CcSEcCtD
Erlotinib—Asthenia—Doxorubicin—pancreatic cancer	1.92e-05	0.000263	CcSEcCtD
Erlotinib—Dizziness—Epirubicin—pancreatic cancer	1.91e-05	0.000262	CcSEcCtD
Erlotinib—Pruritus—Doxorubicin—pancreatic cancer	1.89e-05	0.00026	CcSEcCtD
Erlotinib—Vomiting—Epirubicin—pancreatic cancer	1.84e-05	0.000252	CcSEcCtD
Erlotinib—Diarrhoea—Doxorubicin—pancreatic cancer	1.83e-05	0.000251	CcSEcCtD
Erlotinib—Rash—Epirubicin—pancreatic cancer	1.82e-05	0.00025	CcSEcCtD
Erlotinib—Dermatitis—Epirubicin—pancreatic cancer	1.82e-05	0.00025	CcSEcCtD
Erlotinib—Headache—Epirubicin—pancreatic cancer	1.81e-05	0.000249	CcSEcCtD
Erlotinib—Dizziness—Doxorubicin—pancreatic cancer	1.77e-05	0.000243	CcSEcCtD
Erlotinib—Nausea—Epirubicin—pancreatic cancer	1.72e-05	0.000236	CcSEcCtD
Erlotinib—Vomiting—Doxorubicin—pancreatic cancer	1.7e-05	0.000234	CcSEcCtD
Erlotinib—Rash—Doxorubicin—pancreatic cancer	1.68e-05	0.000232	CcSEcCtD
Erlotinib—Dermatitis—Doxorubicin—pancreatic cancer	1.68e-05	0.000231	CcSEcCtD
Erlotinib—Headache—Doxorubicin—pancreatic cancer	1.67e-05	0.00023	CcSEcCtD
Erlotinib—Nausea—Doxorubicin—pancreatic cancer	1.59e-05	0.000218	CcSEcCtD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	2.32e-06	4.49e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—APOE—pancreatic cancer	2.32e-06	4.49e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PTEN—pancreatic cancer	2.31e-06	4.47e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—EGFR—pancreatic cancer	2.31e-06	4.46e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CTNNB1—pancreatic cancer	2.31e-06	4.46e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CG—pancreatic cancer	2.3e-06	4.45e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CD44—pancreatic cancer	2.28e-06	4.41e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CD44—pancreatic cancer	2.27e-06	4.39e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	2.25e-06	4.35e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PTEN—pancreatic cancer	2.25e-06	4.35e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—STK11—pancreatic cancer	2.25e-06	4.34e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.24e-06	4.32e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—PIK3CA—pancreatic cancer	2.23e-06	4.32e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TERT—pancreatic cancer	2.23e-06	4.3e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—AKT1—pancreatic cancer	2.22e-06	4.3e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.22e-06	4.3e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PIK3CB—pancreatic cancer	2.22e-06	4.3e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PPARG—pancreatic cancer	2.22e-06	4.29e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.22e-06	4.28e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.2e-06	4.26e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GLP1R—pancreatic cancer	2.2e-06	4.25e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GCG—pancreatic cancer	2.19e-06	4.23e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—KRAS—pancreatic cancer	2.18e-06	4.21e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GCG—pancreatic cancer	2.18e-06	4.21e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—AKT1—pancreatic cancer	2.17e-06	4.19e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3CD—pancreatic cancer	2.17e-06	4.19e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—DPYD—pancreatic cancer	2.16e-06	4.18e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—HRAS—pancreatic cancer	2.15e-06	4.16e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—AKT1—pancreatic cancer	2.15e-06	4.16e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—SRC—pancreatic cancer	2.15e-06	4.15e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HIF1A—pancreatic cancer	2.13e-06	4.12e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TSC2—pancreatic cancer	2.12e-06	4.11e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.11e-06	4.07e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TYMP—pancreatic cancer	2.1e-06	4.07e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CG—pancreatic cancer	2.09e-06	4.05e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—VEGFA—pancreatic cancer	2.09e-06	4.04e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—SRC—pancreatic cancer	2.08e-06	4.03e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—APOE—pancreatic cancer	2.08e-06	4.02e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—STAT3—pancreatic cancer	2.07e-06	4e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—HRAS—pancreatic cancer	2.07e-06	4e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NRAS—pancreatic cancer	2.07e-06	3.99e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—STK11—pancreatic cancer	2.06e-06	3.98e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PIK3CB—pancreatic cancer	2.05e-06	3.97e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SLC2A2—pancreatic cancer	2.05e-06	3.96e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—STK11—pancreatic cancer	2.05e-06	3.96e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—TYMS—pancreatic cancer	2.04e-06	3.95e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KDR—pancreatic cancer	2.04e-06	3.94e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTGS2—pancreatic cancer	2.03e-06	3.93e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	2.03e-06	3.92e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CD—pancreatic cancer	2.02e-06	3.91e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PPARG—pancreatic cancer	2.02e-06	3.91e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—STAT3—pancreatic cancer	2.01e-06	3.89e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—NRAS—pancreatic cancer	2.01e-06	3.88e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PIK3CA—pancreatic cancer	2e-06	3.87e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CD44—pancreatic cancer	1.99e-06	3.85e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CTNNB1—pancreatic cancer	1.97e-06	3.81e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.96e-06	3.79e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—SRC—pancreatic cancer	1.96e-06	3.78e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—pancreatic cancer	1.94e-06	3.75e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NFKBIA—pancreatic cancer	1.94e-06	3.74e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.93e-06	3.74e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—TYMS—pancreatic cancer	1.93e-06	3.73e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MYC—pancreatic cancer	1.92e-06	3.72e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.92e-06	3.71e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PTEN—pancreatic cancer	1.92e-06	3.71e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TGFB1—pancreatic cancer	1.92e-06	3.71e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NOTCH1—pancreatic cancer	1.92e-06	3.71e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GCG—pancreatic cancer	1.91e-06	3.69e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—VEGFA—pancreatic cancer	1.91e-06	3.68e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—AKT1—pancreatic cancer	1.9e-06	3.67e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3CB—pancreatic cancer	1.89e-06	3.66e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—NRAS—pancreatic cancer	1.88e-06	3.64e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EGFR—pancreatic cancer	1.88e-06	3.64e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CG—pancreatic cancer	1.88e-06	3.63e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—NRAS—pancreatic cancer	1.88e-06	3.63e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CD44—pancreatic cancer	1.87e-06	3.62e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTGS2—pancreatic cancer	1.87e-06	3.62e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—EGF—pancreatic cancer	1.85e-06	3.58e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HRAS—pancreatic cancer	1.85e-06	3.58e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CD—pancreatic cancer	1.84e-06	3.56e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—EGFR—pancreatic cancer	1.83e-06	3.53e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—AKT1—pancreatic cancer	1.83e-06	3.53e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CTNNB1—pancreatic cancer	1.82e-06	3.52e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GCG—pancreatic cancer	1.8e-06	3.47e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—STK11—pancreatic cancer	1.79e-06	3.47e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.78e-06	3.45e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—SRC—pancreatic cancer	1.78e-06	3.44e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KRAS—pancreatic cancer	1.78e-06	3.44e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTEN—pancreatic cancer	1.77e-06	3.43e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—TYMS—pancreatic cancer	1.77e-06	3.42e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CB—pancreatic cancer	1.76e-06	3.41e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—TYMS—pancreatic cancer	1.76e-06	3.4e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TGFB1—pancreatic cancer	1.75e-06	3.38e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTGS2—pancreatic cancer	1.75e-06	3.38e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KRAS—pancreatic cancer	1.73e-06	3.34e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—STAT3—pancreatic cancer	1.72e-06	3.32e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—NRAS—pancreatic cancer	1.71e-06	3.31e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GLP1R—pancreatic cancer	1.7e-06	3.28e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—STK11—pancreatic cancer	1.69e-06	3.27e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—DPYD—pancreatic cancer	1.67e-06	3.22e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—APOE—pancreatic cancer	1.66e-06	3.21e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CD—pancreatic cancer	1.65e-06	3.19e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—SRC—pancreatic cancer	1.64e-06	3.18e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—AKT1—pancreatic cancer	1.64e-06	3.16e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTEN—pancreatic cancer	1.63e-06	3.16e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PIK3CA—pancreatic cancer	1.63e-06	3.16e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—KRAS—pancreatic cancer	1.62e-06	3.13e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—KRAS—pancreatic cancer	1.61e-06	3.12e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CB—pancreatic cancer	1.6e-06	3.1e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTGS2—pancreatic cancer	1.59e-06	3.07e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CD44—pancreatic cancer	1.59e-06	3.07e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—STAT3—pancreatic cancer	1.59e-06	3.07e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PIK3CA—pancreatic cancer	1.59e-06	3.07e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	1.58e-06	3.06e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—NRAS—pancreatic cancer	1.58e-06	3.06e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—pancreatic cancer	1.58e-06	3.05e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—APOE—pancreatic cancer	1.57e-06	3.04e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.56e-06	3.01e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—TYMS—pancreatic cancer	1.54e-06	2.98e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.54e-06	2.98e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTEN—pancreatic cancer	1.52e-06	2.95e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GCG—pancreatic cancer	1.52e-06	2.94e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HRAS—pancreatic cancer	1.51e-06	2.92e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CG—pancreatic cancer	1.5e-06	2.9e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—PIK3CA—pancreatic cancer	1.49e-06	2.88e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.49e-06	2.87e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—PIK3CA—pancreatic cancer	1.48e-06	2.87e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KRAS—pancreatic cancer	1.48e-06	2.85e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MYC—pancreatic cancer	1.47e-06	2.85e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—TGFB1—pancreatic cancer	1.47e-06	2.84e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HRAS—pancreatic cancer	1.47e-06	2.84e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—TYMS—pancreatic cancer	1.45e-06	2.81e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PPARG—pancreatic cancer	1.45e-06	2.8e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—pancreatic cancer	1.44e-06	2.78e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—APOE—pancreatic cancer	1.44e-06	2.78e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CB—pancreatic cancer	1.44e-06	2.78e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—APOE—pancreatic cancer	1.43e-06	2.77e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—STK11—pancreatic cancer	1.43e-06	2.77e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CG—pancreatic cancer	1.42e-06	2.74e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTEN—pancreatic cancer	1.39e-06	2.68e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CXCL8—pancreatic cancer	1.38e-06	2.67e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—HRAS—pancreatic cancer	1.38e-06	2.66e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HRAS—pancreatic cancer	1.37e-06	2.65e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PPARG—pancreatic cancer	1.37e-06	2.64e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.36e-06	2.64e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—KRAS—pancreatic cancer	1.36e-06	2.63e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.36e-06	2.62e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PIK3CA—pancreatic cancer	1.36e-06	2.62e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.34e-06	2.6e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—AKT1—pancreatic cancer	1.33e-06	2.58e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CASP3—pancreatic cancer	1.32e-06	2.56e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CD—pancreatic cancer	1.32e-06	2.55e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CG—pancreatic cancer	1.3e-06	2.51e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—AKT1—pancreatic cancer	1.3e-06	2.5e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CG—pancreatic cancer	1.29e-06	2.5e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCND1—pancreatic cancer	1.29e-06	2.49e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CTNNB1—pancreatic cancer	1.27e-06	2.46e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—APOE—pancreatic cancer	1.25e-06	2.43e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PPARG—pancreatic cancer	1.25e-06	2.42e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HRAS—pancreatic cancer	1.25e-06	2.42e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PIK3CA—pancreatic cancer	1.25e-06	2.42e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MMP9—pancreatic cancer	1.25e-06	2.41e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PPARG—pancreatic cancer	1.25e-06	2.41e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CD—pancreatic cancer	1.25e-06	2.41e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTEN—pancreatic cancer	1.24e-06	2.4e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—TYMS—pancreatic cancer	1.23e-06	2.38e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CD44—pancreatic cancer	1.23e-06	2.37e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—AKT1—pancreatic cancer	1.22e-06	2.35e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—AKT1—pancreatic cancer	1.21e-06	2.34e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—APOE—pancreatic cancer	1.18e-06	2.29e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GCG—pancreatic cancer	1.18e-06	2.27e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—HRAS—pancreatic cancer	1.16e-06	2.24e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3CA—pancreatic cancer	1.15e-06	2.23e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SRC—pancreatic cancer	1.15e-06	2.23e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	1.15e-06	2.22e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CD—pancreatic cancer	1.14e-06	2.21e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTGS2—pancreatic cancer	1.14e-06	2.2e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CD—pancreatic cancer	1.14e-06	2.2e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CG—pancreatic cancer	1.13e-06	2.19e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—pancreatic cancer	1.12e-06	2.17e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—STAT3—pancreatic cancer	1.11e-06	2.15e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NRAS—pancreatic cancer	1.11e-06	2.14e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—AKT1—pancreatic cancer	1.11e-06	2.14e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—STK11—pancreatic cancer	1.1e-06	2.14e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PPARG—pancreatic cancer	1.09e-06	2.11e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CB—pancreatic cancer	1.09e-06	2.1e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTGS2—pancreatic cancer	1.08e-06	2.08e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CA—pancreatic cancer	1.08e-06	2.08e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	1.07e-06	2.06e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MYC—pancreatic cancer	1.03e-06	2e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PPARG—pancreatic cancer	1.03e-06	1.99e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TGFB1—pancreatic cancer	1.03e-06	1.99e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—AKT1—pancreatic cancer	1.02e-06	1.98e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—APOE—pancreatic cancer	1e-06	1.94e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CB—pancreatic cancer	9.96e-07	1.93e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CD—pancreatic cancer	9.95e-07	1.92e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTEN—pancreatic cancer	9.94e-07	1.92e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CB—pancreatic cancer	9.9e-07	1.91e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTGS2—pancreatic cancer	9.87e-07	1.91e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTGS2—pancreatic cancer	9.81e-07	1.9e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CA—pancreatic cancer	9.78e-07	1.89e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KRAS—pancreatic cancer	9.54e-07	1.84e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TYMS—pancreatic cancer	9.51e-07	1.84e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	9.48e-07	1.83e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—AKT1—pancreatic cancer	9.42e-07	1.82e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTEN—pancreatic cancer	9.39e-07	1.81e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	9.38e-07	1.81e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	9.04e-07	1.75e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—AKT1—pancreatic cancer	8.78e-07	1.7e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CA—pancreatic cancer	8.76e-07	1.69e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PPARG—pancreatic cancer	8.72e-07	1.69e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CB—pancreatic cancer	8.68e-07	1.68e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTEN—pancreatic cancer	8.61e-07	1.66e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTGS2—pancreatic cancer	8.6e-07	1.66e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTEN—pancreatic cancer	8.56e-07	1.65e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—pancreatic cancer	8.48e-07	1.64e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	8.18e-07	1.58e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HRAS—pancreatic cancer	8.11e-07	1.57e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTGS2—pancreatic cancer	8.1e-07	1.57e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—AKT1—pancreatic cancer	7.99e-07	1.54e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	7.95e-07	1.54e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—APOE—pancreatic cancer	7.73e-07	1.49e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTEN—pancreatic cancer	7.5e-07	1.45e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AKT1—pancreatic cancer	7.16e-07	1.38e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTEN—pancreatic cancer	7.07e-07	1.37e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	7.01e-07	1.35e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	6.98e-07	1.35e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	6.93e-07	1.34e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTGS2—pancreatic cancer	6.86e-07	1.33e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PPARG—pancreatic cancer	6.73e-07	1.3e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CA—pancreatic cancer	6.62e-07	1.28e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	6.13e-07	1.19e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CA—pancreatic cancer	6.07e-07	1.17e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CA—pancreatic cancer	6.04e-07	1.17e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTEN—pancreatic cancer	5.99e-07	1.16e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AKT1—pancreatic cancer	5.73e-07	1.11e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AKT1—pancreatic cancer	5.41e-07	1.05e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	5.35e-07	1.03e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS2—pancreatic cancer	5.3e-07	1.02e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CA—pancreatic cancer	5.29e-07	1.02e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	4.98e-07	9.63e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AKT1—pancreatic cancer	4.96e-07	9.59e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AKT1—pancreatic cancer	4.93e-07	9.53e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTEN—pancreatic cancer	4.62e-07	8.93e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AKT1—pancreatic cancer	4.32e-07	8.35e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	4.22e-07	8.16e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AKT1—pancreatic cancer	4.07e-07	7.87e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AKT1—pancreatic cancer	3.45e-07	6.67e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	3.26e-07	6.3e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKT1—pancreatic cancer	2.66e-07	5.15e-06	CbGpPWpGaD
